We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
One stock to keep an eye on is Novartis (NVS - Free Report) . NVS is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock has a Forward P/E ratio of 13.33. This compares to its industry's average Forward P/E of 17.89. Over the last 12 months, NVS's Forward P/E has been as high as 16.06 and as low as 12.50, with a median of 13.82.
Investors should also recognize that NVS has a P/B ratio of 5.15. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 8.16. NVS's P/B has been as high as 5.90 and as low as 4.17, with a median of 5.28, over the past year.
Finally, investors should note that NVS has a P/CF ratio of 9.36. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 26.54. Within the past 12 months, NVS's P/CF has been as high as 14.36 and as low as 8.28, with a median of 9.57.
Another great Large Cap Pharmaceuticals stock you could consider is Pfizer (PFE - Free Report) , which is a # 2 (Buy) stock with a Value Score of A.
Pfizer is currently trading with a Forward P/E ratio of 9.67 while its PEG ratio sits at 0.91. Both of the company's metrics compare favorably to its industry's average P/E of 17.89 and average PEG ratio of 1.40.
Over the last 12 months, PFE's P/E has been as high as 19.41, as low as 8.63, with a median of 11.02, and its PEG ratio has been as high as 2.77, as low as 0.86, with a median of 1.09.
Furthermore, Pfizer holds a P/B ratio of 1.81 and its industry's price-to-book ratio is 8.16. PFE's P/B has been as high as 2.02, as low as 1.52, with a median of 1.76 over the past 12 months.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Novartis and Pfizer are likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, NVS and PFE feels like a great value stock at the moment.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Novartis (NVS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
One stock to keep an eye on is Novartis (NVS - Free Report) . NVS is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock has a Forward P/E ratio of 13.33. This compares to its industry's average Forward P/E of 17.89. Over the last 12 months, NVS's Forward P/E has been as high as 16.06 and as low as 12.50, with a median of 13.82.
Investors should also recognize that NVS has a P/B ratio of 5.15. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 8.16. NVS's P/B has been as high as 5.90 and as low as 4.17, with a median of 5.28, over the past year.
Finally, investors should note that NVS has a P/CF ratio of 9.36. This figure highlights a company's operating cash flow and can be used to find firms that are undervalued when considering their impressive cash outlook. This company's current P/CF looks solid when compared to its industry's average P/CF of 26.54. Within the past 12 months, NVS's P/CF has been as high as 14.36 and as low as 8.28, with a median of 9.57.
Another great Large Cap Pharmaceuticals stock you could consider is Pfizer (PFE - Free Report) , which is a # 2 (Buy) stock with a Value Score of A.
Pfizer is currently trading with a Forward P/E ratio of 9.67 while its PEG ratio sits at 0.91. Both of the company's metrics compare favorably to its industry's average P/E of 17.89 and average PEG ratio of 1.40.
Over the last 12 months, PFE's P/E has been as high as 19.41, as low as 8.63, with a median of 11.02, and its PEG ratio has been as high as 2.77, as low as 0.86, with a median of 1.09.
Furthermore, Pfizer holds a P/B ratio of 1.81 and its industry's price-to-book ratio is 8.16. PFE's P/B has been as high as 2.02, as low as 1.52, with a median of 1.76 over the past 12 months.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Novartis and Pfizer are likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, NVS and PFE feels like a great value stock at the moment.